Alcon (ALC) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached $2.5 billion, up 3% year-over-year (6% in constant currency), with strong performance in Surgical and Vision Care segments.

• Core diluted EPS rose 15% in constant currency to $0.74, while IFRS diluted EPS increased 32% to $0.45.

• Growth was driven by innovative product launches, international expansion, and robust contact lens and implantable sales.

• Regulatory milestones included FDA clearance for Unity Phaco platform and closing of the Belkin acquisition.

• Strategic partnership and licensing agreement with Ocumension in China to commercialize select eye drops, maximizing long-term regional potential.

Financial highlights

• Surgical franchise Q2 revenue was $1.42 billion (+3% reported, +6% constant currency); implantable sales up 9% to $464 million.

• Vision Care Q2 sales reached $1.06 billion (+4% reported, +6% constant currency); contact lens sales up 9% in constant currency.

• Ocular Health Q2 sales up 2% in constant currency, led by Systane; headwinds in contact lens care.

• Free cash flow for 1H24 was $667 million, up from $189 million last year, with operating cash flow at $871 million.

• Cash and cash equivalents stood at $1.4 billion; total debt at $4.7 billion, mostly fixed rate, with no financial covenants.

Outlook and guidance

• FY24 net sales guidance maintained at $9.9–$10.1 billion, with 7–9% constant currency growth expected.

• Core operating margin outlook held at 20.5–21.5%, despite inventory provision pressures.

• Core diluted EPS guidance of $3.00–$3.10, representing 15–18% constant currency growth.

• R&D expense expected at the high end of 7–9% of sales; tax rate to be approximately 20%.

• Interest expense guidance lowered to $160–$180 million.